Bullish drug business probable in the second half of this year

Korea's drug business is likely to be bullish in the second of this year, according to various reports released by some securities and bank analysts, while they worried the domestic cut-throat competition may results in inducing a higher proportion of sales administrative expenses.

Market analysts say the domestic pharmaceutical industry will invariably maintain a stable profit structure due...